Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2014 May 29;0:21–29. doi: 10.1016/j.prostaglandins.2014.05.002

Figure 3.

Figure 3

Relative distribution of all analyzed oxylipins with respect to their precursor LC PUFA. Shown is the pattern for A) total and B) free plasma oxylipins at baseline (t0) and after twelve weeks (t12) of treatment with LC n-3 PUFA. The relative distribution was calculated based on the sum of median concentrations of measured LA-, AA-, ALA-, EPA- and DHA- derived oxylipins.

HHS Vulnerability Disclosure